Evolution of Biologics Screening Technologies

Screening for biologics, in particular antibody drugs, has evolved significantly over the last 20 years. Initially, the screening processes and technologies from many years experience with small molecules were adopted and modified to suit the needs of biologics discovery. Since then, antibody drug discovery has matured significantly and is today investing earlier in new technologies that commercial suppliers are now developing specifically to meet the growing needs of large molecule screening. Here, we review the evolution of screening and automation technologies employed in antibody discovery and highlight the benefits that these changes have brought.

[1]  R. Lequin.  Enzyme immunoassay (EIA)/enzyme-linked immunosorbent assay (ELISA). , 2005, Clinical chemistry.

[2]  Alessandro Spina.  Pharmaceuticals , 2010, European Journal of Risk Regulation.

[3]  Edward M. Goldberg,et al.  Homogeneous Cell- and Bead-Based Assays for High Throughput Screening Using Fluorometric Microvolume Assay Technology , 1999, Journal of biomolecular screening.

[4]  E. F. Ullman,et al.  Luminescent oxygen channeling immunoassay: measurement of particle binding kinetics by chemiluminescence. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Miqin Zhang,et al.  Cellular impedance biosensors for drug screening and toxin detection. , 2007, The Analyst.

[6]  N. Tinel,et al.  A Fluorescent Ligand-Binding Alternative Using Tag-lite® Technology , 2010, Journal of biomolecular screening.

[7]  C. Revankar,et al.  A Homogeneous Fluorescent Live-Cell Assay for Measuring 7-Transmembrane Receptor Activity and Agonist Functional Selectivity Through Beta-Arrestin Recruitment , 2009, Journal of biomolecular screening.

[8]  K. Olson,et al.  A Homogeneous Enzyme Fragment Complementation-Based β-Arrestin Translocation Assay for High-Throughput Screening of G-Protein-Coupled Receptors , 2008, Journal of biomolecular screening.

[9]  Neil D. Cook,et al.  Scintillation proximity assay: a versatile high-throughput screening technology , 1996 .

[10]  R. Karlsson,et al.  Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. , 1991, Journal of immunological methods.

[11]  J. Pons,et al.  Determining kinetics and affinities of protein interactions using a parallel real-time label-free biosensor, the Octet. , 2008, Analytical biochemistry.

[12]  S. Manly,et al.  Use of a Novel Homogeneous Fluorescent Technology in High Throughput Screening , 1996 .

[13]  G. Winter,et al.  Phage antibodies: filamentous phage displaying antibody variable domains , 1990, Nature.

[14]  E. Diamandis,et al.  Ultrasensitive bioanalytical assays using time-resolved fluorescence detection. , 1995, Pharmacology & therapeutics.

[15]  Katherine A. Winters,et al.  Fully Human Monoclonal Antibodies Antagonizing the Glucagon Receptor Improve Glucose Homeostasis in Mice and Monkeys , 2009, Journal of Pharmacology and Experimental Therapeutics.

[16]  C. Hardman,et al.  Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens. , 2008, Protein engineering, design & selection : PEDS.

[17]  Ye Fang,et al.  Evaluation of dynamic mass redistribution technology for pharmacological studies of recombinant and endogenously expressed g protein-coupled receptors. , 2008, Assay and drug development technologies.

[18]  Russell Garlick,et al.  Development of Nonseparation Binding and Functional Assays for G Protein-Coupled Receptors for High Throughput Screening: Pharmacological Characterization of the Immobilized CCR5 Receptor on FlashPlate(r) , 1998 .

[19]  J. Philip McCoy,et al.  High-content screening: getting more from less , 2011, Nature Methods.

[20]  T. Lövgren,et al.  Europium as a label in time-resolved immunofluorometric assays. , 1984, Analytical biochemistry.

[21]  Christopher B. Black,et al.  Cell-based screening using high-throughput flow cytometry. , 2011, Assay and drug development technologies.